<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32628315</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS).</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>390</EndPage><MedlinePgn>379-390</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.15118</ELocationID><Abstract><AbstractText>TDP-43 has been identified as the major component of protein aggregates found in affected neurons in FTLD-TDP and amyotrophic lateral sclerosis (ALS) patients. TDP-43 is hyperphosphorylated, ubiquitinated, and cleaved in the C-terminus. CDC-7 was reported to phosphorylate TDP-43. There are no effective treatments for either FTLD-TDP or ALS, being a pressing need for the search of new therapies. We hypothesized that modulating CDC-7 activity with small molecules that are able to interfere with TDP-43 phosphorylation could be a good therapeutic strategy for these diseases. Here, we have studied the effects of novel brain penetrant, thiopurine-based, CDC-7 inhibitors in TDP-43 homeostasis in immortalized lymphocytes from FTLD-TDP patients, carriers of a loss-of-function GRN mutation, as well as in cells derived from sporadic ALS patients. We found that selective CDC-7 inhibitors, ERP1.14a and ERP1.28a, are able to decrease the enhanced TDP-43 phosphorylation in cells derived from FTLD-TDP and ALS patients and to prevent cytosolic accumulation of TDP-43. Moreover, treatment of FTLD-TDP lymphoblasts with CDC-7 inhibitors leads to recovering the nuclear function of TDP-43-inducing CDK6 repression. We suggest that CDC-7 inhibitors, mainly the heterocyclic compounds here shown, may be considered as promising drug candidates for the ALS/FTD spectrum.</AbstractText><CopyrightInformation>&#xa9; 2020 International Society for Neurochemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaca</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Biomedicine, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Gonzalez</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Structural and Chemical Biology, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biomedicine, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Prats</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Structural and Chemical Biology, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Gracia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Biomedicine, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuevas</LastName><ForeName>Eva P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Structural and Chemical Biology, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Structural and Chemical Biology, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Department of Structural and Chemical Biology, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Requero</LastName><ForeName>&#xc1;ngeles</ForeName><Initials>&#xc1;</Initials><Identifier Source="ORCID">0000-0002-3416-9440</Identifier><AffiliationInfo><Affiliation>Department of Molecular Biomedicine, Centro de Investigaciones Biol&#xf3;gicas, Margarita Salas (CSIC), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CDC-7 inhibitors</Keyword><Keyword MajorTopicYN="N">FTLD-TDP</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">lymphoblasts</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32628315</ArticleId><ArticleId IdType="doi">10.1111/jnc.15118</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Agosta, F., Al-Chalabi, A., Filippi, M., Hardiman, O., Kaji, R., Meininger, V., &#x2026; Ludolph, A. (2015). The El Escorial criteria: Strengths and weaknesses. Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration, 16, 1-7. https://doi.org/10.3109/21678421.2014.964258</Citation></Reference><Reference><Citation>Alquezar, C., Esteras, N., Alzualde, A., Moreno, F., Ayuso, M. S., Lopez de Munain, A., &amp; Mart&#xed;n-Requero, A. (2012). Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-Progranulin mutation c.709-1G&gt;. PLoS One, 7(5), e37057.</Citation></Reference><Reference><Citation>Alquezar, C., Esteras, N., Bartolome, F., Merino, J. J., Alzualde, A., de Munain, A. L., &amp; Mart&#xed;n-Requero, A. (2012). Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G&gt;A PGRN mutation associated with FTLD-TDP dementia. Neurobiology of Aging, 33, 429. e427-e420.</Citation></Reference><Reference><Citation>Alqu&#xe9;zar, C., Esteras, N., de la Encarnaci&#xf3;n, A., Alzualde, A., Moreno, F., L&#xf3;pez de Munain, A., &amp; Mart&#xed;n-Requero, &#xc1;. (2014). PGRN haploinsufficiency increased Wnt5a signaling in peripheral cells from frontotemporal lobar degeneration-progranulin mutation carriers. Neurobiology of Aging, 35, 886-898. https://doi.org/10.1016/j.neurobiolaging.2013.09.021</Citation></Reference><Reference><Citation>Alquezar, C., Salado, I. G., de la Encarnacion, A., Perez, D. I., Moreno, F., Gil, C., &#x2026; Mart&#xed;n-Requero, A. (2016). Targeting TDP-43 phosphorylation by Casein Kinase-1delta inhibitors: A novel strategy for the treatment of frontotemporal dementia. Molecular Neurodegeneration, 11, 36.</Citation></Reference><Reference><Citation>Ayala, Y. M., Misteli, T., &amp; Baralle, F. E. (2008). TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proceedings of the National Academy of Sciences of the United States of America, 105, 3785-3789. https://doi.org/10.1073/pnas.0800546105</Citation></Reference><Reference><Citation>Benajiba, L., Le Ber, I., Camuzat, A., Lacoste, M., Thomas-Anterion, C., Couratier, P., &#x2026; Clinical, F. (2009). TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology, 65, 470-473.</Citation></Reference><Reference><Citation>Brooks, B. R., Miller, R. G., Swash, M., &amp; Munsat, T. L. (2000). El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 293-299. https://doi.org/10.1080/146608200300079536</Citation></Reference><Reference><Citation>Buratti, E. (2018). TDP-43 post-translational modifications in health and disease. Expert Opinion on Therapeutic Targets, 22, 279-293. https://doi.org/10.1080/14728222.2018.1439923</Citation></Reference><Reference><Citation>Burrell, J. R., Halliday, G. M., Kril, J. J., Ittner, L. M., G&#xf6;tz, J., Kiernan, M. C., &amp; Hodges, J. R. (2016). The frontotemporal dementia-motor neuron disease continuum. Lancet, 388, 919-931. https://doi.org/10.1016/S0140-6736(16)00737-6</Citation></Reference><Reference><Citation>Canosa, A., Calvo, A., Moglia, C., Iazzolino, B., Brunetti, M., Restagno, G., &#x2026; Chi&#xf2;, A. (2014). A familial ALS case carrying a novel p. G147C SOD1 heterozygous missense mutation with non-executive cognitive impairment. Journal of Neurology, Neurosurgery, and Psychiatry, 85, 1437-1439.</Citation></Reference><Reference><Citation>Choksi, D. K., Roy, B., Chatterjee, S., Yusuff, T., Bakhoum, M. F., Sengupta, U., &#x2026; Jackson, G. R. (2014). TDP-43 Phosphorylation by casein kinase Iepsilon promotes oligomerization and enhances toxicity in vivo. Human Molecular Genetics, 23, 1025-1035.</Citation></Reference><Reference><Citation>Couratier, P., Corcia, P., Lautrette, G., Nicol, M., &amp; Marin, B. (2017). ALS and frontotemporal dementia belong to a common disease spectrum. Revue Neurologique, 173, 273-279. https://doi.org/10.1016/j.neurol.2017.04.001</Citation></Reference><Reference><Citation>Devenney, E., Vucic, S., Hodges, J. R., &amp; Kiernan, M. C. (2015). Motor neuron disease-frontotemporal dementia: A clinical continuum. Expert Review of Neurotherapeutics, 15, 509-522. https://doi.org/10.1586/14737175.2015.1034108</Citation></Reference><Reference><Citation>Di, L., Kerns, E. H., Fan, K., McConnell, O. J., &amp; Carter, G. T. (2003). High throughput artificial membrane permeability assay for blood-brain barrier. European Journal of Medicinal Chemistry, 38, 223-232. https://doi.org/10.1016/S0223-5234(03)00012-6</Citation></Reference><Reference><Citation>Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., &#x2026; Akiyama, H. (2008). Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of Neurology, 64, 60-70. https://doi.org/10.1002/ana.21425</Citation></Reference><Reference><Citation>Heyburn, L., &amp; Moussa, C. E. (2017). TDP-43 in the spectrum of MND-FTLD pathologies. Molecular and Cellular Neurosciences, 83, 46-54. https://doi.org/10.1016/j.mcn.2017.07.001</Citation></Reference><Reference><Citation>Hodges, J. R., Davies, R. R., Xuereb, J. H., Casey, B., Broe, M., Bak, T. H., &#x2026; Halliday, G. M. (2004). Clinicopathological correlates in frontotemporal dementia. Annals of Neurology, 56, 399-406. https://doi.org/10.1002/ana.20203</Citation></Reference><Reference><Citation>Ibarreta, D., Parrilla, R., &amp; Ayuso, M. S. (1997). Altered Ca2+ homeostasis in lymphoblasts from patients with late-onset Alzheimer disease. Alzheimer Disease and Associated Disorders, 11, 220-227.</Citation></Reference><Reference><Citation>Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., &#x2026; Rouleau, G. A. (2008). TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics, 40, 572-574. https://doi.org/10.1038/ng.132</Citation></Reference><Reference><Citation>Kim, J. M., Yamada, M., &amp; Masai, H. (2003). Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. Mutation Research, 532, 29-40. https://doi.org/10.1016/j.mrfmmm.2003.08.008</Citation></Reference><Reference><Citation>Lagier-Tourenne, C., &amp; Cleveland, D. W. (2009). Rethinking ALS: The FUS about TDP-43. Cell, 136, 1001-1004. https://doi.org/10.1016/j.cell.2009.03.006</Citation></Reference><Reference><Citation>Lattante, S., Ciura, S., Rouleau, G. A., &amp; Kabashi, E. (2015). Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends in Genetics : TIG, 31, 263-273. https://doi.org/10.1016/j.tig.2015.03.005</Citation></Reference><Reference><Citation>Liachko, N. F., McMillan, P. J., Guthrie, C. R., Bird, T. D., Leverenz, J. B., &amp; Kraemer, B. C. (2013). CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Annals of Neurology, 74, 39-52. https://doi.org/10.1002/ana.23870</Citation></Reference><Reference><Citation>Liachko, N. F., McMillan, P. J., Strovas, T. J., Loomis, E., Greenup, L., Murrell, J. R., &#x2026; Kraemer, B. C. (2014). The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genetics, 10, e1004803. https://doi.org/10.1371/journal.pgen.1004803</Citation></Reference><Reference><Citation>Ling, S. C., Polymenidou, M., &amp; Cleveland, D. W. (2013). Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron, 79, 416-438. https://doi.org/10.1016/j.neuron.2013.07.033</Citation></Reference><Reference><Citation>Liscic, R. M. (2015). Molecular basis of ALS and FTD: Implications for translational studies. Arhiv Za Higijenu Rada I Toksikologiju, 66, 285-290.</Citation></Reference><Reference><Citation>Lul&#xe9;, D., B&#xf6;hm, S., M&#xfc;ller, H.-P., Aho-&#xd6;zhan, H., Keller, J., Gorges, M., &#x2026; Ludolph, A. C. (2018). Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior, 101, 163-171. https://doi.org/10.1016/j.cortex.2018.01.004</Citation></Reference><Reference><Citation>Mart&#xed;nez, A., P&#xe9;rez, D. I., Gil, C., Mart&#xed;n-Requero, A., Rojas-Prats, E., Mart&#xed;nez-Gonz&#xe1;lez, L., &amp; P&#xe9;rez, C. CDC7-inhibitor compounds and use thereof for the treatment of neurological conditions. WO2018/172587, March 22, 2017.</Citation></Reference><Reference><Citation>Moujalled, D., James, J. L., Parker, S. J., Lidgerwood, G. E., Duncan, C., Meyerowitz, J., &#x2026; White, A. R. (2013). Kinase inhibitor screening identifies cyclin-dependent kinases and glycogen synthase kinase 3 as potential modulators of TDP-43 cytosolic accumulation during cell stress. PLoS One, 8, e67433. https://doi.org/10.1371/journal.pone.0067433</Citation></Reference><Reference><Citation>Neumann, M. (2013). Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: Molecular similarities and differences. Revue Neurologique, 169, 793-798.</Citation></Reference><Reference><Citation>Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., &#x2026; Lee, V.- M.-Y. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133. https://doi.org/10.1126/science.1134108</Citation></Reference><Reference><Citation>Nguyen, H. P., Van Broeckhoven, C., &amp; van der Zee, J. (2018). ALS genes in the genomic era and their implications for FTD. Trends in Genetics: TIG, 34, 404-423. https://doi.org/10.1016/j.tig.2018.03.001</Citation></Reference><Reference><Citation>Nonaka, T., Suzuki, G., Tanaka, Y., Kametani, F., Hirai, S., Okado, H., &#x2026; Hasegawa, M. (2016). Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1delta triggers Mislocalization and accumulation of TDP-43. Journal of Biological Chemistry, 291, 5473-5483.</Citation></Reference><Reference><Citation>Palomo, V., Tosat-Bitrian, C., Nozal, V., Nagaraj, S., Martin-Requero, A., &amp; Martinez, A. (2019). TDP-43, A key therapeutic target beyond amyotrophic lateral sclerosis. ACS Chemical Neuroscience, 10, 1183-1196.</Citation></Reference><Reference><Citation>Phukan, J., Elamin, M., Bede, P., Jordan, N., Gallagher, L., Byrne, S., &#x2026; Hardiman, O. (2012). The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study. Journal of Neurology, Neurosurgery, and Psychiatry, 83, 102-108. https://doi.org/10.1136/jnnp-2011-300188</Citation></Reference><Reference><Citation>Posa, D., Mart&#xed;nez-Gonz&#xe1;lez, L., Bartolom&#xe9;, F., Nagaraj, S., Porras, G., Mart&#xed;nez, A., &amp; Mart&#xed;n-Requero, &#xc1;. (2019). Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. Molecular Neurobiology, 56, 2424-2432. https://doi.org/10.1007/s12035-018-1249-8</Citation></Reference><Reference><Citation>Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., &amp; Patel, B. K. (2019). Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 12, 25. https://doi.org/10.3389/fnmol.2019.00025</Citation></Reference><Reference><Citation>Rohrer, J. D., Guerreiro, R., Vandrovcova, J., Uphill, J., Reiman, D., Beck, J., &#x2026; Rossor, M. N. (2009). The heritability and genetics of frontotemporal lobar degeneration. Neurology, 73, 1451-1456. https://doi.org/10.1212/WNL.0b013e3181bf997a</Citation></Reference><Reference><Citation>Rojas-Prats, E., Martinez-Gonzalez, L., Liachko, N. F., Gonzalo, C., P&#xe9;rez, C., Petralla, S., Monti, B., Kraemer, B. C., Martin-Requero, A., Gil, C., Perez, D. I., De Lago, E., &amp; Martinez, A. Targeting nuclear protein TDP-43 by Cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis (Submitted).</Citation></Reference><Reference><Citation>Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., &#x2026; Shaw, C. E. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (New York, NY), 319, 1668-1672. https://doi.org/10.1126/science.1154584</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>